Insulet (Nasdaq:PODD) announced today that it made its Omnipod 5 automated insulin delivery system available in several new geographies.

Insulet (PODD) announced its revolutionary Omnipod 5 Automated Insulin Delivery System is now available in Australia and will soon be offered ...

Dexcom, a medical device manufacturer that develops continuous glucose monitoring systems, received a warning letter from the FDA regarding manufacturing processes at its facilities in San Diego and ...

Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...

Dexcom, the local maker of continuous glucose monitors, received a warning letter from the Food and Drug Administration last ...

DexCom Inc. closed 50.22% short of its 52-week high of $142.00, which the company achieved on March 26th.

This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss how continuous glucose monitoring (CGM) adoption impacts clinical inertia and ...

This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss the key benefits of continuous glucose monitoring (CGM) technology compared with ...

DexCom Inc. closed 51.77% below its 52-week high of $142.00, which the company achieved on March 26th.

Insulet Corporation (NASDAQ:PODD) showcases a strong financial performance with a ROIC of 16.28% and a WACC of 10.24%, ...

NSYNC entertainer diagnosed with rare form of diabetes that happens in adulthood but is more like Type 1 than Type 2.